SK285905B6 - Feromónová kompozícia získateľná zo sekrétu izolovaného z pokožky z okolia mliečnych žliaz cicavca a jej použitie - Google Patents

Feromónová kompozícia získateľná zo sekrétu izolovaného z pokožky z okolia mliečnych žliaz cicavca a jej použitie Download PDF

Info

Publication number: SK285905B6
Authority: SK; Slovakia
Prior art keywords: acid; derivatives; weight; pheromone composition; pheromone
Prior art date: 1998-01-21

Application number

SK1090-2000A

Other languages

English (en)

Slovak (sk)

Other versions

SK10902000A3 (sk

Inventor

Patrick Pageat

Original Assignee

Fideline

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-21

Filing date

1999-01-21

Publication date

2007-10-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31950877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK285905(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-01-21 Application filed by Fideline filed Critical Fideline

2001-02-12 Publication of SK10902000A3 publication Critical patent/SK10902000A3/sk

2007-10-04 Publication of SK285905B6 publication Critical patent/SK285905B6/sk

Links

239000000203 mixture Substances 0.000 title claims abstract description 161
239000003016 pheromone Substances 0.000 title claims abstract description 121
230000028327 secretion Effects 0.000 title claims abstract description 22
210000004907 gland Anatomy 0.000 title abstract description 5
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 114
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 63
235000021314 Palmitic acid Nutrition 0.000 claims abstract description 57
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 55
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 55
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 55
239000005642 Oleic acid Substances 0.000 claims abstract description 55
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 55
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 55
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 55
241000124008 Mammalia Species 0.000 claims abstract description 48
235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 40
229930195729 fatty acid Natural products 0.000 claims abstract description 40
239000000194 fatty acid Substances 0.000 claims abstract description 40
150000004665 fatty acids Chemical class 0.000 claims abstract description 34
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims abstract description 31
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims abstract description 25
235000021360 Myristic acid Nutrition 0.000 claims abstract description 25
208000019901 Anxiety disease Diseases 0.000 claims abstract description 22
150000001298 alcohols Chemical class 0.000 claims abstract description 17
230000036506 anxiety Effects 0.000 claims abstract description 16
150000002148 esters Chemical class 0.000 claims abstract description 15
238000006243 chemical reaction Methods 0.000 claims abstract description 14
150000002576 ketones Chemical class 0.000 claims abstract description 13
150000003839 salts Chemical class 0.000 claims abstract description 13
150000002170 ethers Chemical class 0.000 claims abstract description 12
238000004519 manufacturing process Methods 0.000 claims abstract description 10
239000003814 drug Substances 0.000 claims abstract description 8
208000015181 infectious disease Diseases 0.000 claims abstract description 8
206010001488 Aggression Diseases 0.000 claims abstract description 6
230000004580 weight loss Effects 0.000 claims abstract description 6
239000004480 active ingredient Substances 0.000 claims abstract description 4
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 70
235000021313 oleic acid Nutrition 0.000 claims description 54
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 43
239000005639 Lauric acid Substances 0.000 claims description 32
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 27
235000020778 linoleic acid Nutrition 0.000 claims description 27
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 27
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 26
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 25
241001465754 Metazoa Species 0.000 claims description 22
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 20
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
239000002253 acid Substances 0.000 claims description 15
239000002904 solvent Substances 0.000 claims description 15
210000005075 mammary gland Anatomy 0.000 claims description 13
230000016571 aggressive behavior Effects 0.000 claims description 12
150000001412 amines Chemical class 0.000 claims description 11
229920001451 polypropylene glycol Polymers 0.000 claims description 11
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 9
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 9
235000012000 cholesterol Nutrition 0.000 claims description 9
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 9
235000013305 food Nutrition 0.000 claims description 9
YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 claims description 9
229940031439 squalene Drugs 0.000 claims description 9
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 9
150000001875 compounds Chemical class 0.000 claims description 7
239000002453 shampoo Substances 0.000 claims description 7
239000007921 spray Substances 0.000 claims description 7
239000000443 aerosol Substances 0.000 claims description 6
NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 6
235000021355 Stearic acid Nutrition 0.000 claims description 5
229930182558 Sterol Natural products 0.000 claims description 5
208000012761 aggressive behavior Diseases 0.000 claims description 5
SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 5
239000000945 filler Substances 0.000 claims description 5
239000011159 matrix material Substances 0.000 claims description 5
231100000252 nontoxic Toxicity 0.000 claims description 5
230000003000 nontoxic effect Effects 0.000 claims description 5
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
150000003432 sterols Chemical class 0.000 claims description 5
235000003702 sterols Nutrition 0.000 claims description 5
239000008117 stearic acid Substances 0.000 claims description 4
229960000735 docosanol Drugs 0.000 claims description 3
230000006400 anxiety behaviour Effects 0.000 claims description 2
RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 claims description 2
SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims 8
235000021319 Palmitoleic acid Nutrition 0.000 claims 4
150000001735 carboxylic acids Chemical class 0.000 claims 4
125000003158 alcohol group Chemical group 0.000 claims 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 2
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 1
229960002446 octanoic acid Drugs 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 40
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 abstract 1
235000020661 alpha-linolenic acid Nutrition 0.000 abstract 1
150000001408 amides Chemical class 0.000 abstract 1
229960004488 linolenic acid Drugs 0.000 abstract 1
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 abstract 1
239000000902 placebo Substances 0.000 description 59
229940068196 placebo Drugs 0.000 description 59
241000282887 Suidae Species 0.000 description 47
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 42
208000027418 Wounds and injury Diseases 0.000 description 36
230000035882 stress Effects 0.000 description 33
101001017254 Homo sapiens Myb-binding protein 1A Proteins 0.000 description 30
101000582992 Homo sapiens Phospholipid phosphatase-related protein type 5 Proteins 0.000 description 30
102100034005 Myb-binding protein 1A Human genes 0.000 description 30
239000000243 solution Substances 0.000 description 30
230000006378 damage Effects 0.000 description 26
208000014674 injury Diseases 0.000 description 26
238000011156 evaluation Methods 0.000 description 22
230000000694 effects Effects 0.000 description 20
-1 ACTH Chemical compound 0.000 description 18
238000000034 method Methods 0.000 description 18
241000282472 Canis lupus familiaris Species 0.000 description 17
208000021017 Weight Gain Diseases 0.000 description 16
235000019786 weight gain Nutrition 0.000 description 16
230000004584 weight gain Effects 0.000 description 16
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
230000006399 behavior Effects 0.000 description 13
235000021051 daily weight gain Nutrition 0.000 description 13
239000000126 substance Substances 0.000 description 13
238000012360 testing method Methods 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
241000282898 Sus scrofa Species 0.000 description 12
230000007717 exclusion Effects 0.000 description 12
238000002474 experimental method Methods 0.000 description 11
102100039377 28 kDa heat- and acid-stable phosphoprotein Human genes 0.000 description 10
101710176122 28 kDa heat- and acid-stable phosphoprotein Proteins 0.000 description 10
206010052428 Wound Diseases 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
KZJWDPNRJALLNS-FBZNIEFRSA-N clionasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-FBZNIEFRSA-N 0.000 description 10
235000011187 glycerol Nutrition 0.000 description 10
238000004949 mass spectrometry Methods 0.000 description 10
210000005069 ears Anatomy 0.000 description 9
150000004702 methyl esters Chemical class 0.000 description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
230000000474 nursing effect Effects 0.000 description 9
241000894007 species Species 0.000 description 9
ARYTXMNEANMLMU-UHFFFAOYSA-N 24alpha-methylcholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(C)C(C)C)C1(C)CC2 ARYTXMNEANMLMU-UHFFFAOYSA-N 0.000 description 8
ARYTXMNEANMLMU-ATEDBJNTSA-N campestanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]2(C)CC1 ARYTXMNEANMLMU-ATEDBJNTSA-N 0.000 description 8
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
241000283903 Ovis aries Species 0.000 description 7
244000309466 calf Species 0.000 description 7
230000037406 food intake Effects 0.000 description 7
235000012631 food intake Nutrition 0.000 description 7
230000008774 maternal effect Effects 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
241000283707 Capra Species 0.000 description 6
FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 6
QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
230000036541 health Effects 0.000 description 6
238000007619 statistical method Methods 0.000 description 6
238000001356 surgical procedure Methods 0.000 description 6
QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 5
BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 5
LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 5
KZJWDPNRJALLNS-STIDJNKJSA-N gamma-sitosterol Natural products CC[C@@H](CC[C@@H](C)[C@@H]1CC[C@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C KZJWDPNRJALLNS-STIDJNKJSA-N 0.000 description 5
NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 5
ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 4
SOFRHZUTPGJWAM-UHFFFAOYSA-N 3-hydroxy-4-[(2-methoxy-5-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound COc1ccc(cc1N=Nc1c(O)c(cc2ccccc12)C(=O)Nc1cccc(c1)[N+]([O-])=O)[N+]([O-])=O SOFRHZUTPGJWAM-UHFFFAOYSA-N 0.000 description 4
241000283690 Bos taurus Species 0.000 description 4
101100438971 Caenorhabditis elegans mat-1 gene Proteins 0.000 description 4
HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 4
HJZLEGIHUQOJBA-UHFFFAOYSA-N cyclohexane propionic acid Chemical compound OC(=O)CCC1CCCCC1 HJZLEGIHUQOJBA-UHFFFAOYSA-N 0.000 description 4
229960000890 hydrocortisone Drugs 0.000 description 4
238000000926 separation method Methods 0.000 description 4
230000004037 social stress Effects 0.000 description 4
GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
230000034994 death Effects 0.000 description 3
231100000517 death Toxicity 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
239000007789 gas Substances 0.000 description 3
210000004392 genitalia Anatomy 0.000 description 3
239000003176 neuroleptic agent Substances 0.000 description 3
230000035935 pregnancy Effects 0.000 description 3
230000002028 premature Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000000932 sedative agent Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
QYIXCDOBOSTCEI-BPAAZKTESA-N (8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1CC2CC(O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QYIXCDOBOSTCEI-BPAAZKTESA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
101100379068 Caenorhabditis elegans apc-2 gene Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
206010011469 Crying Diseases 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
208000016952 Ear injury Diseases 0.000 description 2
241000283086 Equidae Species 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
UAGJVSRUFNSIHR-UHFFFAOYSA-N Methyl levulinate Chemical compound COC(=O)CCC(C)=O UAGJVSRUFNSIHR-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
206010036590 Premature baby Diseases 0.000 description 2
208000010399 Wasting Syndrome Diseases 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000008484 agonism Effects 0.000 description 2
239000000556 agonist Substances 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
238000004891 communication Methods 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
230000003203 everyday effect Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
235000021588 free fatty acids Nutrition 0.000 description 2
238000004817 gas chromatography Methods 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
235000013372 meat Nutrition 0.000 description 2
YYRDDAPQDPABPZ-UHFFFAOYSA-N methyl dec-5-enoate Chemical compound CCCCC=CCCCC(=O)OC YYRDDAPQDPABPZ-UHFFFAOYSA-N 0.000 description 2
IZFGRAGOVZCUFB-UHFFFAOYSA-N methyl hexadec-9-enoate Chemical compound CCCCCCC=CCCCCCCCC(=O)OC IZFGRAGOVZCUFB-UHFFFAOYSA-N 0.000 description 2
235000019645 odor Nutrition 0.000 description 2
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
210000002990 parathyroid gland Anatomy 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
239000004089 psychotropic agent Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
229940125723 sedative agent Drugs 0.000 description 2
230000001624 sedative effect Effects 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
230000011273 social behavior Effects 0.000 description 2
238000005507 spraying Methods 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
FWNZKPKGBYWNJO-KVVVOXFISA-N (z)-octadec-9-enoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O FWNZKPKGBYWNJO-KVVVOXFISA-N 0.000 description 1
BBNYCLAREVXOSG-UHFFFAOYSA-N 2-palmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CO)CO BBNYCLAREVXOSG-UHFFFAOYSA-N 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
KRVXMNNRSSQZJP-PHFHYRSDSA-N 5alpha-androst-16-en-3alpha-ol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CC[C@H]21 KRVXMNNRSSQZJP-PHFHYRSDSA-N 0.000 description 1
QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 1
208000025940 Back injury Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
208000027534 Emotional disease Diseases 0.000 description 1
QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
239000005792 Geraniol Substances 0.000 description 1
GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010053759 Growth retardation Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
QYDYPVFESGNLHU-ZHACJKMWSA-N Methyl (9E)-9-octadecenoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OC QYDYPVFESGNLHU-ZHACJKMWSA-N 0.000 description 1
241000282579 Pan Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000008601 Polycythemia Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
206010042434 Sudden death Diseases 0.000 description 1
241000906446 Theraps Species 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
230000004913 activation Effects 0.000 description 1
201000009840 acute diarrhea Diseases 0.000 description 1
210000004404 adrenal cortex Anatomy 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229940061641 androsterone Drugs 0.000 description 1
229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
229940054051 antipsychotic indole derivative Drugs 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000005667 attractant Substances 0.000 description 1
XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
229950003616 azaperone Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
KRVXMNNRSSQZJP-UHFFFAOYSA-N beta-androstenol Natural products C1C(O)CCC2(C)C3CCC(C)(C=CC4)C4C3CCC21 KRVXMNNRSSQZJP-UHFFFAOYSA-N 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000001914 calming effect Effects 0.000 description 1
QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
230000035602 clotting Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000002633 crown compound Substances 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
238000009826 distribution Methods 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
230000008451 emotion Effects 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
229940113087 geraniol Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
231100000001 growth retardation Toxicity 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
230000005802 health problem Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
244000144980 herd Species 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
150000002475 indoles Chemical class 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000009027 insemination Effects 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000002075 main ingredient Substances 0.000 description 1
230000013011 mating Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229960004815 meprobamate Drugs 0.000 description 1
ODPLFJYILBATKC-FOCLMDBBSA-N methyl (e)-hexadec-2-enoate Chemical compound CCCCCCCCCCCCC\C=C\C(=O)OC ODPLFJYILBATKC-FOCLMDBBSA-N 0.000 description 1
PVVODBCDJBGMJL-CMDGGOBGSA-N methyl (e)-octadec-11-enoate Chemical compound CCCCCC\C=C\CCCCCCCCCC(=O)OC PVVODBCDJBGMJL-CMDGGOBGSA-N 0.000 description 1
KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical class COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
WTTJVINHCBCLGX-UHFFFAOYSA-N methyl octadeca-9,12-dienoate Chemical compound CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
210000000607 neurosecretory system Anatomy 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
230000002474 noradrenergic effect Effects 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000000849 parathyroid Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
LUALIOATIOESLM-UHFFFAOYSA-N periciazine Chemical compound C1CC(O)CCN1CCCN1C2=CC(C#N)=CC=C2SC2=CC=CC=C21 LUALIOATIOESLM-UHFFFAOYSA-N 0.000 description 1
229960000769 periciazine Drugs 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
229960002695 phenobarbital Drugs 0.000 description 1
150000002990 phenothiazines Chemical class 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
244000144977 poultry Species 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
229960003111 prochlorperazine Drugs 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
229940001470 psychoactive drug Drugs 0.000 description 1
230000000506 psychotropic effect Effects 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
NNNVXFKZMRGJPM-KHPPLWFESA-N sapienic acid Chemical compound CCCCCCCCC\C=C/CCCCC(O)=O NNNVXFKZMRGJPM-KHPPLWFESA-N 0.000 description 1
210000001732 sebaceous gland Anatomy 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
230000003997 social interaction Effects 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
MHRFLGDBPPPYBG-UHFFFAOYSA-N stigmasta-3,5,22-trien-7-one Natural products C1CC=CC2=CC(=O)C3C4CCC(C(C)C=CC(CC)C(C)C)C4(C)CCC3C21C MHRFLGDBPPPYBG-UHFFFAOYSA-N 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000012085 test solution Substances 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1
239000012855 volatile organic compound Substances 0.000 description 1
239000002699 waste material Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Immunology (AREA)
Virology (AREA)
Zoology (AREA)
Emergency Medicine (AREA)
Anesthesiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Cosmetics (AREA)
Fodder In General (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Feed For Specific Animals (AREA)
Compounds Of Iron (AREA)
Preventing Corrosion Or Incrustation Of Metals (AREA)

SK1090-2000A 1998-01-21 1999-01-21 Feromónová kompozícia získateľná zo sekrétu izolovaného z pokožky z okolia mliečnych žliaz cicavca a jej použitie SK285905B6 (sk)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
NO980282A NO308197B1 (no)	1998-01-21	1998-01-21	Sammensetning og oppløsning derav for Õ minske stress, angst og agressivitet hos pattedyr inneholdende en blanding av fettsyrer eller derivater derav
US09/010,515 US6077867A (en)	1998-01-21	1998-01-21	Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
JP00980298A JP4750232B2 (ja)	1998-01-21	1998-01-21	ストレス、不安および攻撃性を低減するブタ鎮静フェロモン
CA2227706A CA2227706C (fr)	1998-01-21	1998-01-21	Pheromones d'apaisement pour diminuer le stress, l'anxiete et l'agressivite de porcs
EP98400117A EP0948963B1 (fr)	1998-01-21	1998-01-21	Compositions contenant des phéromones pour soulager le stress, l'anxiété et l'agressivité chez les cochons
PCT/EP1999/000375 WO1999037297A1 (fr)	1998-01-21	1999-01-21	Pheromones calmant les cochons, utilisees pour diminuer le stress, l'anxiete et l'agressivite
CZ20002700A CZ20002700A3 (cs)	1998-01-21	1999-01-21	Uklidňující feromonové prostředky pro snížení stresu, úzkosti a agresivity prasat

Publications (2)

Publication Number	Publication Date
SK10902000A3 SK10902000A3 (sk)	2001-02-12
SK285905B6 true SK285905B6 (sk)	2007-10-04

Family

ID=31950877

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1090-2000A SK285905B6 (sk)	1998-01-21	1999-01-21	Feromónová kompozícia získateľná zo sekrétu izolovaného z pokožky z okolia mliečnych žliaz cicavca a jej použitie

Country Status (21)

Country	Link
US (2)	US6077867A (fr)
EP (2)	EP0948963B1 (fr)
JP (1)	JP4750232B2 (fr)
CN (1)	CN1217659C (fr)
AT (2)	ATE239464T1 (fr)
AU (1)	AU760614B2 (fr)
BR (1)	BRPI9907151C1 (fr)
CA (2)	CA2227706C (fr)
CZ (1)	CZ20002700A3 (fr)
DE (2)	DE69814343T2 (fr)
DK (2)	DK0948963T3 (fr)
ES (2)	ES2198661T3 (fr)
HU (1)	HU226882B1 (fr)
IL (1)	IL137257A0 (fr)
NO (2)	NO308197B1 (fr)
NZ (1)	NZ505813A (fr)
PL (1)	PL199144B1 (fr)
PT (2)	PT948963E (fr)
SK (1)	SK285905B6 (fr)
WO (1)	WO1999037297A1 (fr)
ZA (1)	ZA99426B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6323237B1 (en) *	1997-03-17	2001-11-27	Btg International Limited	Therapeutic compositions
US20090253781A1 (en) *	2002-05-24	2009-10-08	Btg International Limited	Therapeutic compositions
US6054481A (en) *	1998-01-21	2000-04-25	Fideline	Pig appeasing pheromones for enhancing weight gain in a mammal
JP4754688B2 (ja) *	1998-01-21	2011-08-24	フィドゥラン	ストレス、不安及び攻撃性を低減するブタ鎮静フェロモン
CA2388754C (fr) *	1999-10-13	2010-07-13	Marco A. Chacon	Intervention therapeutique visant a reproduire l'effet d'une restriction calorique
AU2001266082B2 (en)	2000-07-14	2006-03-16	Societe Des Produits Nestle S.A.	Dietary lipids for improving skin and coat of pets
FR2815227B1 (fr) *	2000-10-17	2003-04-11	Schwartz Laboratoires Robert	Composition anti-stress destinee a etre incorporee principalement a des vehicules nutritionnels
ES2186576B1 (es) *	2001-10-11	2004-09-16	Universitat De Les Illes Balears	Acido 2-hidroxioleico para utilizar como medicamento.
WO2004000336A1 (fr) *	2002-06-19	2003-12-31	Fideline	Pheromones apaisantes aviaires destinees a diminuer le stress, l'anxiete et l'agressivite
DE60332635D1 (de)	2002-06-19	2010-07-01	Fideline Le Rieu Neuf	Beruhigende vogel-pheromone zur verminderung von stress, angst und aggressivität
KR100700884B1 (ko)	2002-11-14	2007-03-29	백융기	약학적으로 유용한 노화 및 스트레스 조절용 신규 페로몬 화합물 및 그 분리정제방법
GB0420856D0 (en) *	2004-09-20	2004-10-20	Ketocytonyx Inc	Cns modulators
EP2527447A1 (fr)	2004-06-03	2012-11-28	Athlomics Pty Ltd	Agents et procédés pour diagnostiquer le stress
WO2006020137A2 (fr) *	2004-07-16	2006-02-23	Ketocytonyx Inc.	Composes oligomere
US7485743B2 (en) *	2004-07-20	2009-02-03	Btg International Limited	Oligomeric ketone compounds
US20070225252A1 (en) *	2004-07-23	2007-09-27	Gross Richard A	Ketogenic Saccharides
US20070197645A1 (en) *	2004-09-21	2007-08-23	Martin Keith F	Treatment of adhd
DK1796658T3 (en) *	2004-09-21	2016-06-27	Btg Int Ltd	dopaminergic mimetics
US20090275670A1 (en) *	2008-04-30	2009-11-05	Marshall Gerald L	Dog pheromone formulation and delivery system
FR2931676B1 (fr) *	2008-05-30	2011-01-14	Ceva Sante Animale	Nouveaux modes d'administration d'un melange d'acides gras pour le traitement de mammiferes non humains
KR20110070861A (ko)	2008-09-18	2011-06-24	얀센 파마슈티카 엔.브이.	항생제 사용을 감소시키기 위한 아자페론의 용도
WO2010044648A1 (fr)	2008-10-16	2010-04-22	Ragasa Industrias S.A. De C.V.	Huile végétale de haute pureté diélectrique, procédé d'obtention et son utilisation dans un appareil électrique
US20100163020A1 (en) *	2008-12-30	2010-07-01	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Method for administering an inhalable compound
US8481020B2 (en)	2009-12-21	2013-07-09	Sergeant's Pet Care Products, Inc.	Pheromone compositions and methods of use
US8871190B2 (en)	2009-04-25	2014-10-28	Sergeant's Pet Care Products, Inc.	Polymeric pheromone formulation and method of use to calm stress-related behavior in mammals over an extended period of time
CN103126886A (zh) *	2011-05-13	2013-06-05	中国农业科学院北京畜牧兽医研究所	一种仔猪安抚剂释放盒
CN102240279B (zh) *	2011-05-13	2013-04-10	中国农业科学院北京畜牧兽医研究所	一种仔猪安抚剂及其制备方法和应用
US9480688B2 (en)	2011-09-20	2016-11-01	Sergeant's Pet Care Products, Inc.	Pheromone compositions and their use to modify behavior in different vertebrate species
WO2013043896A1 (fr)	2011-09-20	2013-03-28	Sergeant's Pet Care Products, Inc.	Compositions d'interomone et leur utilisation pour modifier le comportement chez différentes espèces vertébrées
US9314018B2 (en)	2012-06-25	2016-04-19	Institut de Recherche en Semiochimie et Ethologie Appliquee	Feline scratch marking semiochemicals
CA2943085C (fr)	2014-03-18	2022-12-13	Institut de Recherche en Semiochimie et Ethologie Appliquee	Compositions semiochimiques pour reduire les conflits sociaux chez les chats
MX2016012112A (es) *	2014-03-18	2017-04-06	Inst De Rech En Semiochimie Et Ethologie Appliquee	Feromona tranquilizadora para gatos.
EP2926809A1 (fr) *	2014-03-31	2015-10-07	Ceva Sante Animale	Compositions à base de phéromones destinées à traiter les problèmes comportementaux ou médicaux liés au stress des mammifères non humains
FR3031039B1 (fr) *	2014-12-24	2018-03-02	Virbac	Composition apaisante pour animaux comprenant au moins un acide gras et de la nepetalactone
FR3031104B1 (fr)	2014-12-26	2017-01-06	Melchior Material & Life Science France	Composition pro-pheromonale apaisante pour les mammiferes
CA2973626A1 (fr)	2015-01-23	2016-07-28	Pork Crc Ltd	Produit et procede procurant enrichissement et facilitant l'expression de comportements naturels chez les porcs
AU2016221929A1 (en) *	2015-02-20	2017-07-13	Société des Produits Nestlé S.A.	Medium chain fatty acids and their triglycerides for treating anxiety
EP3124020A1 (fr)	2015-07-31	2017-02-01	Ceva Sante Animale	Compositions de phéromones et utilisations de celles-ci
FR3046334B1 (fr)	2015-12-31	2020-03-06	Melchior Material And Life Science France	Composition solide pour le relargage controle de substances semiochimiques
EP3661600A4 (fr)	2017-10-23	2021-08-11	Epitracker, Inc.	Analogues d'acides gras et leur utilisation dans le traitement des états liés au syndrome métabolique
KR101994338B1 (ko) *	2017-10-25	2019-06-28	엘지이노텍 주식회사	사육장 관리 장치 및 방법
EP3727457B1 (fr)	2017-12-22	2025-08-20	Ceva Santé Animale	Diffuseurs de composition de semio-chimiques régulés en fonction de la température
JP2021525249A (ja)	2018-05-23	2021-09-24	エピトラッカーインコーポレイテッドＥｐｉｔｒａｃｋｅｒ，Ｉｎｃ．	加齢及び長期性の質に関連する状態の診断及び治療のための組成物及び方法
WO2020146263A1 (fr)	2019-01-09	2020-07-16	Epitracker, Inc.	Compositions et méthodes pour le diagnostic et le traitement de maladies neurodégénératives
JP7404382B2 (ja)	2019-03-04	2023-12-25	エピトラッカーインコーポレイテッド	脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
WO2021055926A1 (fr) *	2019-09-19	2021-03-25	Texas Tech University System	Phéromone néonatale maternelle porcine
MX2022008617A (es) *	2020-02-19	2022-10-10	Marel Meat As	Metodo y sistema para preaturdimiento y/o aturdimiento de animales.
WO2022040346A1 (fr) *	2020-08-20	2022-02-24	Epitracker, Inc.	Compositions et méthodes d'amélioration de l'humeur
CN117083062A (zh) *	2020-10-19	2023-11-17	第二基因组公司	用于治疗孤独症谱系障碍的方法
CN112370528B (zh) *	2020-10-23	2022-04-08	宁波三生生物科技股份有限公司	一种具标识功能的信息素组合物及其制剂
WO2023080939A1 (fr)	2021-11-03	2023-05-11	Epitracker, Inc.	Pentadécanoylcarnitine pour le traitement d'affections liées à la qualité du vieillissement et à la longévité
CN114452238B (zh) *	2022-01-07	2023-10-27	佛山市南海东方澳龙制药有限公司	具有安抚作用的宠物药浴香波及其制备方法
AU2022447402A1 (en)	2022-03-14	2024-08-29	Fera Diagnostics And Biologicals Corp.	Fatty acid compositions
CN117322521A (zh) *	2023-10-20	2024-01-02	中国农业大学	十五烷酸在缓解动物断奶应激中的应用
EP4595749A1 (fr)	2024-02-02	2025-08-06	Signs	Procédé de libération d'un produit semiochimique dans l'environnement par diffusion passive, système et moyens, notamment bâtonnets, à cet effet, et leurs utilisations
CN120938981A (zh) *	2025-10-20	2025-11-14	宁波三生生物科技股份有限公司	一种信息素组合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS61249371A (ja) *	1985-04-30	1986-11-06	Nippon Oil & Fats Co Ltd	栄養飲料組成物
JP3039817B2 (ja) *	1990-09-28	2000-05-08	株式会社資生堂	シャンプー組成物
ES2034888B1 (es) *	1991-07-11	1994-02-16	Madaus Cerafarm Lab	Procedimiento de obtencion de la fraccion acida total de los extractos lipidicos de los frutos del sabal serrulata.
US5425963A (en) *	1991-09-17	1995-06-20	Church & Dwight Co., Inc.	High purity fatty acid salt products
WO1993011987A1 (fr) *	1991-12-13	1993-06-24	Viktor Nikolaevich Kizilov	Vehicule sur coussin d'air
SE9200541D0 (sv) *	1992-02-24	1992-02-24	Kabi Pharmacia Ab	New usee of omega-3-fatty acids
AU3472193A (en) *	1992-03-20	1993-10-21	Church & Dwight Company, Inc.	Encapsulated dietary fatty acid salt products
WO1994015464A1 (fr) *	1993-01-15	1994-07-21	Abbott Laboratories	Lipides structures
DK0724832T3 (da) *	1995-02-03	2000-04-10	Fideline	Egenskaber ved kattes faciale feromoner
DE19511572C2 (de) *	1995-03-29	1998-02-26	Henkel Kgaa	Niedrigviskose Trübungsmittelkonzentrate
DE19615777C2 (de) *	1996-04-20	1999-04-01	Henkel Kgaa	Verwendung von Milchsäure-Milchsäureester-Mischungen
JP4754688B2 (ja) *	1998-01-21	2011-08-24	フィドゥラン	ストレス、不安及び攻撃性を低減するブタ鎮静フェロモン

1998
- 1998-01-21 DK DK98400117T patent/DK0948963T3/da active
- 1998-01-21 PT PT98400117T patent/PT948963E/pt unknown
- 1998-01-21 AT AT98400117T patent/ATE239464T1/de active
- 1998-01-21 US US09/010,515 patent/US6077867A/en not_active Expired - Lifetime
- 1998-01-21 JP JP00980298A patent/JP4750232B2/ja not_active Expired - Lifetime
- 1998-01-21 EP EP98400117A patent/EP0948963B1/fr not_active Expired - Lifetime
- 1998-01-21 ES ES98400117T patent/ES2198661T3/es not_active Expired - Lifetime
- 1998-01-21 NO NO980282A patent/NO308197B1/no not_active IP Right Cessation
- 1998-01-21 DE DE69814343T patent/DE69814343T2/de not_active Expired - Lifetime
- 1998-01-21 CA CA2227706A patent/CA2227706C/fr not_active Expired - Lifetime
1999
- 1999-01-21 CZ CZ20002700A patent/CZ20002700A3/cs unknown
- 1999-01-21 ES ES99903663T patent/ES2234236T3/es not_active Expired - Lifetime
- 1999-01-21 DK DK99903663T patent/DK1047415T3/da active
- 1999-01-21 IL IL13725799A patent/IL137257A0/xx active IP Right Grant
- 1999-01-21 EP EP99903663A patent/EP1047415B1/fr not_active Expired - Lifetime
- 1999-01-21 PL PL341867A patent/PL199144B1/pl unknown
- 1999-01-21 NZ NZ505813A patent/NZ505813A/en not_active IP Right Cessation
- 1999-01-21 SK SK1090-2000A patent/SK285905B6/sk not_active IP Right Cessation
- 1999-01-21 CA CA2318392A patent/CA2318392C/fr not_active Expired - Lifetime
- 1999-01-21 PT PT99903663T patent/PT1047415E/pt unknown
- 1999-01-21 BR BRPI9907151A patent/BRPI9907151C1/pt not_active IP Right Cessation
- 1999-01-21 AU AU24237/99A patent/AU760614B2/en not_active Expired
- 1999-01-21 HU HU0101312A patent/HU226882B1/hu unknown
- 1999-01-21 WO PCT/EP1999/000375 patent/WO1999037297A1/fr not_active Ceased
- 1999-01-21 ZA ZA9900426A patent/ZA99426B/xx unknown
- 1999-01-21 DE DE69922633T patent/DE69922633T2/de not_active Expired - Lifetime
- 1999-01-21 AT AT99903663T patent/ATE284688T1/de active
- 1999-01-21 CN CN998032190A patent/CN1217659C/zh not_active Expired - Lifetime
2000
- 2000-07-19 NO NO20003693A patent/NO329205B1/no not_active IP Right Cessation
- 2000-07-21 US US09/621,554 patent/US6384252B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DK1047415T3 (da)	2005-04-25
DE69922633T2 (de)	2005-12-15
IL137257A0 (en)	2001-07-24
EP0948963A1 (fr)	1999-10-13
PT948963E (pt)	2003-09-30
CZ20002700A3 (cs)	2000-12-13
DE69814343T2 (de)	2003-12-24
JP4750232B2 (ja)	2011-08-17
BRPI9907151B1 (pt)	2016-02-16
CA2227706A1 (fr)	1999-07-21
ES2234236T3 (es)	2005-06-16
HU226882B1 (en)	2010-01-28
HUP0101312A3 (en)	2005-11-28
DE69814343D1 (de)	2003-06-12
PL199144B1 (pl)	2008-08-29
PL341867A1 (en)	2001-05-07
CA2318392C (fr)	2011-11-15
CN1291093A (zh)	2001-04-11
US6384252B1 (en)	2002-05-07
NO20003693L (no)	2000-09-20
EP1047415A1 (fr)	2000-11-02
WO1999037297A1 (fr)	1999-07-29
CN1217659C (zh)	2005-09-07
JPH11209293A (ja)	1999-08-03
EP0948963B1 (fr)	2003-05-07
SK10902000A3 (sk)	2001-02-12
HUP0101312A2 (hu)	2001-08-28
DE69922633D1 (de)	2005-01-20
DK0948963T3 (da)	2003-08-11
BRPI9907151B8 (pt)	2017-11-14
NZ505813A (en)	2003-07-25
NO980282L (no)	1999-07-22
PT1047415E (pt)	2005-04-29
AU2423799A (en)	1999-08-09
NO308197B1 (no)	2000-08-14
ATE284688T1 (de)	2005-01-15
CA2318392A1 (fr)	1999-07-29
NO20003693D0 (no)	2000-07-19
BR9907151A (pt)	2000-10-24
ATE239464T1 (de)	2003-05-15
EP1047415B1 (fr)	2004-12-15
NO980282D0 (no)	1998-01-21
US6077867A (en)	2000-06-20
ES2198661T3 (es)	2004-02-01
BRPI9907151C1 (pt)	2021-05-25
NO329205B1 (no)	2010-09-13
CA2227706C (fr)	2010-08-03
ZA99426B (en)	1999-07-21
AU760614B2 (en)	2003-05-22

Publication	Publication Date	Title
SK285905B6 (sk)	2007-10-04	Feromónová kompozícia získateľná zo sekrétu izolovaného z pokožky z okolia mliečnych žliaz cicavca a jej použitie
Christensen et al.	2011	Effects of repeated regrouping on horse behaviour and injuries
Pulliam et al.	1989	Safety of ivermectin in target animals
US6169113B1 (en)	2001-01-02	Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
JP4754688B2 (ja)	2011-08-24	ストレス、不安及び攻撃性を低減するブタ鎮静フェロモン
Roelofs et al.	2008	The effect of fenceline bull exposure on expression of oestrus in dairy cows
US12310937B2 (en)	2025-05-27	Fatty acid compositions
Le Neindre	1991	Effects of breed and early social environment on calf behaviour
Munari	2021	EVALUATION OF RABBIT PRODUCTION AND WELFARE
MXPA00007189A (en)	2002-03-05	Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
Zaenuri et al.	2025	Effect of progesterone levels in hand-made sponges for estrus synchronization on reproductive performance of Etawah goats
KR20110084162A (ko)	2011-07-21	성장성 향상을 위한 아자페론의 용도
Mbaya et al.	2006	Mixed Infection of Notodres cati and Ancylostoma caninum Among Captive Lions (Panthera leo) at the Sanda Kyarimi Park, Maiduguri, Nigeria
van Erp-van der Kooij et al.	0	CAN WE PREDICT BEHAVIOUR IN PIGS?-SEARCHING FOR CONSISTENCY IN BEHAVIOUR OVER TIME AND ACROSS SITUATIONS

Legal Events

Date	Code	Title	Description
2019-03-01	MK4A	Patent expired	Expiry date: 20190121